Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Tilgen

Showing results (151-160 of 156) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 156 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Interlaboratory evaluation of a new reverse transcriptase polymerase chain reaction-based enzyme-linked immunosorbent assay for the detection of circulating melanoma cells: a multicenter study of the Dermatologic Cooperative Oncology GroupU Reinhold, C Berkin, A K Bosserhoff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2008
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)K Spieth, R Kaufmann, R Dummer, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|March 22, 2003
[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma]F Mornex, L Thomas, P Mohr, et al.
Melanoma Research|February 6, 2003
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanomaF Mornex, L Thomas, P Mohr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanomaM R Middleton, J J Grob, N Aaronson, et al.
Journal of Medical Genetics|February 4, 2005
Mutational spectrum of NSDHL in CHILD syndromeD Bornholdt, A König, R Happle, et al.
Pageof 16

Showing results (151-160 of 156) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 156 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Interlaboratory evaluation of a new reverse transcriptase polymerase chain reaction-based enzyme-linked immunosorbent assay for the detection of circulating melanoma cells: a multicenter study of the Dermatologic Cooperative Oncology GroupU Reinhold, C Berkin, A K Bosserhoff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2008
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)K Spieth, R Kaufmann, R Dummer, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|March 22, 2003
[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma]F Mornex, L Thomas, P Mohr, et al.
Melanoma Research|February 6, 2003
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanomaF Mornex, L Thomas, P Mohr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanomaM R Middleton, J J Grob, N Aaronson, et al.
Journal of Medical Genetics|February 4, 2005
Mutational spectrum of NSDHL in CHILD syndromeD Bornholdt, A König, R Happle, et al.
Pageof 16